CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study

doi:10.3389/fonc.2020.00057

CORC > 自动化研究所 > 中国科学院自动化研究所 > 中国科学院分子影像重点实验室

	CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study
	Li, Hailin 1,2; Zhang, Rui 1; Wang, Siwen 2,5; Fang, Mengjie 2,5; Zhu, Yongbei 2,3; Hu, Zhenhua 2,5; Dong, Di 2,5; Shi, Jingyun 4; Tian, Jie 2,3
刊名	FRONTIERS IN ONCOLOGY
	2020-02-18
卷号	10 页码:9
关键词	computed tomography radiomics non-small-cell lung cancer tyrosine kinase inhibitor resistance anaplastic lymphoma kinase
ISSN号	2234-943X
DOI	10.3389/fonc.2020.00057
通讯作者	Hu, Zhenhua(zhenhua.hu@ia.ac.cn) ; Dong, Di(di.dong@ia.ac.cn) ; Shi, Jingyun(shijingyun89179@126.com) ; Tian, Jie(jie.tian@ia.ac.cn)
英文摘要	Objectives: To identify a computed tomography (CT)-based radiomic signature for predicting progression-free survival (PFS) in stage IV anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitor (TKI) crizotinib. Materials and Methods: This retrospective proof-of-concept study included a cohort of 63 stage IV ALK-positive NSCLC patients who had received TKI crizotinib therapy for model construction and validation. Another independent cohort including 105 stage IV EGFR-positive NSCLC patients was also used for external validation in EGFR-TKI treatment. We initially extracted 481 quantitative three-dimensional features derived from manually segmented tumor volumes of interest. Pearson's correlation analysis along with the least absolute shrinkage and selection operator (LASSO) penalized Cox proportional hazards regression was successively performed to select critical radiomic features. A CT-based radiomic signature for PFS prediction was obtained using multivariate Cox regression. The performance evaluation of the radiomic signature was conducted using the concordance index (C-index), time-dependent receiver operating characteristic (ROC) analysis, and Kaplan-Meier survival analysis. Results: A radiomic signature containing three features showed significant prognostic performance for ALK-positive NSCLC patients in both the training cohort (C-index, 0.744; time-dependent AUC, 0.895) and the validation cohort (C-index, 0.717; time-dependent AUC, 0.824). The radiomic signature could significantly risk-stratify ALK-positive NSCLC patients (hazard ratio, 2.181; P < 0.001) and outperformed other prognostic factors. However, no significant association with PFS was captured for the radiomic signature in the EGFR-positive NSCLC cohort (log-rank tests, P = 0.41). Conclusions: The CT-based radiomic features can capture valuable information regarding the tumor phenotype. The proposed radiomic signature was found to be an effective prognostic factor in stage IV ALK mutated nonsynchronous nodules in NSCLC patients treated with a TKI.
资助项目	National Key R&D Program of China[2017YFC1308700] ; National Key R&D Program of China[2017YFA0205200] ; National Key R&D Program of China[2017YFC1309100] ; National Key R&D Program of China[2016YFC0102600] ; National Key R&D Program of China[2016YFA0100900] ; National Key R&D Program of China[2016YFA0100902] ; National Natural Science Foundation of China[91959130] ; National Natural Science Foundation of China[81971776] ; National Natural Science Foundation of China[81771924] ; National Natural Science Foundation of China[81501616] ; National Natural Science Foundation of China[61622117] ; National Natural Science Foundation of China[81671759] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[81671851] ; National Natural Science Foundation of China[81527805] ; Beijing Natural Science Foundation[L182061] ; Beijing Natural Science Foundation[JQ19027] ; Bureau of International Cooperation of Chinese Academy of Sciences[173211KYSB20160053] ; Beijing Nova Program[Z181100006218046] ; Scientific Instrument Developing Project of the Chinese Academy of Sciences[YZ201502] ; Scientific Instrument Developing Project of the Chinese Academy of Sciences[YZ201672] ; Youth Innovation Promotion Association CAS[2017175]
WOS关键词	TYROSINE KINASE ; RESISTANCE ; CHEMOTHERAPY ; REGRESSION ; INHIBITOR
WOS研究方向	Oncology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000518612200001
资助机构	National Key R&D Program of China ; National Natural Science Foundation of China ; Beijing Natural Science Foundation ; Bureau of International Cooperation of Chinese Academy of Sciences ; Beijing Nova Program ; Scientific Instrument Developing Project of the Chinese Academy of Sciences ; Youth Innovation Promotion Association CAS
内容类型	期刊论文
源URL	[http://ir.ia.ac.cn/handle/173211/38333]
专题	自动化研究所_中国科学院分子影像重点实验室
通讯作者	Hu, Zhenhua; Dong, Di; Shi, Jingyun; Tian, Jie
作者单位	1.Harbin Univ Sci & Technol, Sch Automat, Harbin, Peoples R China 2.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing, Peoples R China 3.Beihang Univ, Sch Med, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing, Peoples R China 4.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Radiol, Shanghai, Peoples R China 5.Univ Chinese Acad Sci, Sch Artificial Intelligence, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Li, Hailin,Zhang, Rui,Wang, Siwen,et al. CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study[J]. FRONTIERS IN ONCOLOGY,2020,10:9.
APA	Li, Hailin.,Zhang, Rui.,Wang, Siwen.,Fang, Mengjie.,Zhu, Yongbei.,...&Tian, Jie.(2020).CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study.FRONTIERS IN ONCOLOGY,10,9.
MLA	Li, Hailin,et al."CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study".FRONTIERS IN ONCOLOGY 10(2020):9.